Passive, prioritization-only notification that analyzes adult chest X-ray images for suspected pleural effusion and/or pneumothorax and provides case-level output in the PACS/workstation for worklist prioritization within standard-of-care workflow, without sending proactive alerts to specialists.
Images and patients
X-ray/Radiography · Chest
Key limitation
Keep in mind: No proactive alert; no image alteration or queue removal; not diagnostic or standalone for clinical decisions; negative cases remain for routine review.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Passively triage adult chest radiographs for suspected pleural effusion and/or pneumothorax.
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest Input: Adult frontal chest X-ray DICOM images.
Who uses it?Intended users: Appropriately trained medical specialists qualified to interpret chest radiographs
What does the software produce?Output: Case-level flag or blank for worklist prioritization or triage; the analysis result can also be provided as DICOM, while the technologist notification is contextual only.
What is its most important limitation?Key limitation: No proactive alert; no image alteration or queue removal; not diagnostic or standalone for clinical decisions; negative cases remain for routine review.
Evidence takeaway. Evidence from the reviewed source record: FDA reports non-clinical testing: effusion AUC 0.9864, sensitivity 94.29%, specificity 95.72%; pneumothorax AUC 0.9973, sensitivity 96.08%, specificity 99.14%. The clinical set had 1,708 radiographs: 754 effusion and 954 pneumothorax; clinical effusion AUC/sensitivity/specificity were 0.9686/89.86%/93.48%, and pneumothorax values were 0.9630/88.92%/90.51%.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Passive, prioritization-only notification that analyzes adult chest X-ray images for suspected pleural effusion and/or pneumothorax and provides case-level output in the PACS/workstation for worklist prioritization within standard-of-care workflow, without sending proactive alerts to specialists.
Exact FDA submission
Checked 2026-11-14
Packet wording: "analyzes adult chest X-ray images for the presence of pre-specified suspected critical findings (pleural effusion and/or pneumothorax)." … "provides case-level output available in the PACS/workstation for worklist prioritization or triage.". Read from the exact FDA decision document on 2026-11-14.
Case-level flag or blank for worklist prioritization or triage; the analysis result can also be provided as DICOM, while the technologist notification is contextual only.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
No proactive alert; no image alteration or queue removal; not diagnostic or standalone for clinical decisions; negative cases remain for routine review.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
FDA reports non-clinical testing: effusion AUC 0.9864, sensitivity 94.29%, specificity 95.72%; pneumothorax AUC 0.9973, sensitivity 96.08%, specificity 99.14%. The clinical set had 1,708 radiographs: 754 effusion and 954 pneumothorax; clinical effusion AUC/sensitivity/specificity were 0.9686/89.86%/93.48%, and pneumothorax values were 0.9630/88.92%/90.51%.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA reports non-clinical testing: effusion AUC 0.9864, sensitivity 94.29%, specificity 95.72%; pneumothorax AUC 0.9973, sensitivity 96.08%, specificity 99.14%. The clinical set had 1,708 radiographs: 754 effusion and 954 pneumothorax; clinical effusion AUC/sensitivity/specificity were 0.9686/89.86%/93.48%, and pneumothorax values were 0.9630/88.92%/90.51%.
FDA source
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Lunit INSIGHT CXR Triage- Pneumothorax regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K211733
Samplen=954
Sites3
IndependenceIndependence not established
K211733
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K211733. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: The exact-submission ACR model card explicitly references DICOM and PACS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Lunit INSIGHT CXR Triage as software that, when deployed on radiological imaging equipment, runs automatically after image acquisition and displays results through the PACS/workstation worklist interface. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "When deployed on other radiological imaging equipment, Lunit INSIGHT CXR Triage automatically runs after image acquisition." … "It prioritizes and displays the analysis result through the worklist interface of PACS/workstation.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Case-level flag or blank for worklist prioritization or triage; the analysis result can also be provided as DICOM, while the technologist notification is contextual only.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Case-level flag or blank for worklist prioritization or triage; the analysis result can also be provided as DICOM, while the technologist notification is contextual only.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Lunit INSIGHT CXR Triage as software that, when deployed on radiological imaging equipment, runs automatically after image acquisition and displays results through the PACS/workstation worklist interface. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "When deployed on other radiological imaging equipment, Lunit INSIGHT CXR Triage automatically runs after image acquisition." … "It prioritizes and displays the analysis result through the worklist interface of PACS/workstation.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact-submission ACR model card explicitly references DICOM and PACS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Exact FDA submission
Checked 2026-09-01
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Lunit's information security page states the company is ISO/IEC 27001 certified, with ISO 13485 and MDSAP at its manufacturing site. Company-level; the page gives no scope, dates or product controls.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for Lunit INSIGHT CXR Triage; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K211733 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Triage and prioritization of adult chest X-ray cases suggestive of vertebral compression fracture, including use in Bone Health and Fracture Liaison Service programs.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.